Immunochemistry showed CD45, BCL-2, BCL-6, CD10, CD20, and CD79a positivity and CD30, MUM1
, EBER, and CD34 negativity.
Along with the diagnosis, there is an increasing need to evaluate prognostic markers like CD10, BCL2, BCL6 and MUM1
to subcategorize DLBCL into Germinal Centre (GC) type or Activated B Cell (ABC) type as they have different survival rates.
The percentage of cells stained with MUM1
showed a significantly positive correlation with the percentage of cells expressing bcl-2 (p=0.
In addition, there is greater variability in the nuclear size and morphology, and most cases of BL in the HIV setting express MUM1
The expression of BCL6, MUM1
and CD138 in these lymphomas corresponds to the stage from which they are thought to develop [13,14].
patients express cytoplasmic immunoglobulin, CD38, CD138, and IRF4/ MUM1
and are usually negative or only weakly positive for CD45, CD20, and PAX5.
Plasmablastic lymphoma characteristically shows immunophenotypic evidence of terminal B-cell differentiation with expression of CD38, CD138, and MUM1
They are also frequently positive for MUM1
(75%), BCL6 (46%), BCL2 (78%), and CD23 (70%).
As mentioned earlier, MUM1
protein expression is common in C-ALCL and ALK+ and ALK- ALCL, making the biologic significance of IRF4 translocation uncertain at the present time.
The antibodies were specific for CD5 (Labvision/Neomarker, Montreal, Quebec, Canada), CD10 (Novocastra/Vision Biosystem, Benton Lane, Newcastle upon Tyne, United Kingdom), CD20 (Dako, Carpinteria, California), CD30 (Dako), CD138 (Serotec, Raleigh, North Carolina), PAX5 (Transduction Labs, San Diego, California), BCL2 (Novocastra/Vision Biosystem), BCL6 (Dako), MUM1
(Santa Cruz Biotechnology, Santa Cruz, California), ALK (Dako), MIB-1 (Ki-67, Dako), p53 (Dako), and p63 (clone 4A4, Santa Cruz Biotechnology).
13) Sections were incubated at room temperature for 30 minutes with the following antibody panel: CD3, CD20, BCL-2, CD30, CD43, CD10, CD5, CD23, CD27, BCL-6, CD38, PAX5, MUM1
, latent membrane protein (LMP-1), AID, and [kappa] and [lambda] light chains (Table 1).
Primary bone lymphoma can be further divided into germinal-center B-cell type and non-germinal-center B-cell type by using CD10, BCL6, and MUM1
antibodies (Figure 1, B through D).